Sociodemographic disparities in prostate cancer imaging.

Imaging is central to the diagnosis, staging, treatment planning, and monitoring of prostate cancer (PCa). Unequal access to new imaging techniques may directly contribute to gaps in PCa treatment and outcome. Thus, identifying disparities in PCa diagnosis and treatment are centrla to informing strategies to promote equitable cancer care. This review examines the existing evidence regarding clinical and sociodemographic factors associated with disparities in imaging utilization and treatment for PCa. Major areas of disparities identified include healthcare and research access. Sociodemographic disparities are present in screening and diagnosis; Black patients are consistently less likely to receive both prostate multiparametric MRI and timely molecular imaging used to evaluate for biochemical recurrence. Regional variation in appropriate and inappropriate diagnostic imaging also contributes to corresponding differences in outcomes, especially between urban and rural settings. Delays in PCa imaging and diagnosis also delay definitive treatment or placement on active surveillance, with prominent differences by race and measures of social advantage Recognition of these disparities in PCa imaging and treatment can reinforce actions to improve equitable access to patients affected by PCa. Identifying modifiable steps in the PCa diagnosis, staging, and treatment workflow may inform interventions to bridge gaps in cancer outcome.